MET and lung carcinoma: It was reported that engaging the overexpressed MET in lung cancers with a biparatopic ADC, METxMET‐M114, provided more benefits than merely blocking the MET function and had the potential to overcome acquired resistance to MET‐selective tyrosine kinase inhibitors.131